Alphabet Stock Slides as AI Talent Exodus and SpaceX Losses Shake Investor Confidence 
SpaceX Stock Rebounds After Sharp Selloff, But Valuation Concerns Persist 
FedEx Stock Drops After Weak 2026 Earnings Forecast Despite Strong Q4 Results 
Ryan Cohen Rejects GameStop Pay Package, Prepares New eBay Acquisition Plan 
Cerebras Revenue Forecast Tops Expectations, but Margin Concerns Weigh on Stock 
Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive 
KPMG Australia Chairman and Senior Partners Exit Amid Escalating Whistleblower Scandal 
DOJ Opens Investigation Into NYC Coffee Shop Over Anti-Goldman Social Media Post 
Apollo Debt Solutions Limits Redemptions as Withdrawal Requests Surge 
Nike CFO Shake-Up Fuels Concerns Over Turnaround Strategy 
Baseten Secures $1.5 Billion Funding at $13 Billion Valuation Amid AI Infrastructure Boom 
Oracle Cuts 21,000 Jobs as AI Reshapes Workforce and Cloud Expansion Accelerates 
WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
Qualcomm Nears $4 Billion Acquisition of AI Chip Startup Modular 
JPMorgan Sees Strong Strategic Value in Potential AbbVie Acquisition of Apogee Therapeutics 
Meta Reportedly Developing ‘Arena’ Prediction Market App to Rival Polymarket and Kalshi 
OXFORD, United Kingdom, Feb. 17, 2016 -- Summit Therapeutics plc (NASDAQ:SMMT) (LSE:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection, announces that management will participate in one on one meetings at SunTrust Robinson Humphrey’s 2016 Orphan Drug Day, taking place 23 February 2016 in New York City.
A copy of the presentation will be available through the Investors section on the Company’s website, www.summitplc.com.
About Summit Therapeutics
Summit is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease, Duchenne muscular dystrophy, and the infectious disease, Clostridium difficile infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).
For more information, please contact:
| Summit Glyn Edwards / Richard Pye (UK office) Erik Ostrowski / Michelle Avery (US office) | Tel: +44 (0)1235 443 951 +1 617 225 4455 | ||
| Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray / Tony Rawlinson | Tel: +44 (0)20 77148 7900 | ||
| N+1 Singer (Broker) Aubrey Powell / Jen Boorer | Tel: +44 (0)20 7496 3000 | ||
| Peckwater PR (Financial public relations, UK) Tarquin Edwards | Tel: +44 (0)7879 458 364 [email protected] | ||
| MacDougall Biomedical Communications (US media contact) Chris Erdman | Tel: +1 781 235 3060 [email protected] | ||
-END-
